Pharmacopsychiatry 2009; 42(1): 14-19
DOI: 10.1055/s-0028-1085438
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

Rosiglitazone in the Assistance of Metabolic Control during Olanzapine Administration in Schizophrenia: A Pilot Double-blind, Placebo-controlled, 12-week Trial

T. Baptista 1 , N. Rangel 2 , Y. El Fakih 3 , E. Uzcátegui 3 , T. Galeazzi 4 , S. Beaulieu 5 , E. Araujo de Baptista 6
  • 1Department of Physiology, Los Andes University Medical School, Mérida, Venezuela
  • 2Psychiatric Institute “Dr. Raúl Castillo”, Peribeca, San Cristóbal, Táchira State, Venezuela
  • 3Department of Psychiatry, Los Andes University Medical School, Mérida, Venezuela
  • 4LABIMET, Los Andes University Medical School, San Cristóbal, Venezuela
  • 5Douglas Hospital Research Center, McGill University, Montreal, QC, Canada
  • 6Pharmacy School, Department of Microbiology, Los Andes University Medical School, Mérida, Venezuela
Weitere Informationen

Publikationsverlauf

received 05.05.2008 revised 13.06.2008

accepted 09.07.2008

Publikationsdatum:
19. Januar 2009 (online)

Preview

Abstract

Introduction: Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients.

Methods: Thirty patients taking olanzapine (10–20 mg daily for 8 months) were randomly allocated to rosiglitazone (n=15; 4 to 8 mg daily) or placebo (n=15) in a 12-week double-blind protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks 6 and 12.

Results: The rosiglitazone and placebo groups gained 3.2±4.5 and 2.2±2.3 kg, respectively (p=0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p<0.05). Rosiglitazone did not improve the lipid profile, fibrinogen and Hb1c levels.

Discussion: The positive impact of rosiglitazone was limited to improved glycemic control. It cannot be recommended for metabolic control during olanzapine treatment.

References

Correspondence

Prof. T. BaptistaMD, PhD 

Department of Physiology

Los Andes University Medical School

P.O. Box 93

Mérida 5101-A

Venezuela

Telefon: +58/274/240 31 10

Fax: +58/274/263 63 95

eMail: trinbap@yahoo.com